Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03331250
Recruitment Status : Recruiting
First Posted : November 6, 2017
Last Update Posted : August 10, 2018
Eisai Inc.
Information provided by (Responsible Party):
Gregory Cote, Massachusetts General Hospital

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : May 31, 2021
  Estimated Study Completion Date : May 31, 2025